TIDMHIK 
 
RNS Number : 6599V 
Hikma Pharmaceuticals Plc 
04 November 2010 
 

 
 
                 Hikma Pharmaceuticals PLC - Share Transactions 
 
LONDON, 4 November 2010: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: 
HIK), in accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, 
announces that Mr. Said Darwazah, a Director and Person Discharging Managerial 
Responsibility has undertaken transactions in the Company's Ordinary Shares of 
10p each. The transactions took place in London as detailed below. 
 
On 2 - 3 November 2010, Mr Darwazah disposed of 300,000 Ordinary Shares of 10p 
each, representing 0.15 per cent. of the issued share capital of the Company, at 
an average price of 778.63 pence per Ordinary Share. The primary purpose of this 
disposal is to fund the establishment of the Samih Darwazah Center for 
Innovation Management and Entrepreneurship at the American University of Beirut 
in Lebanon. 
 
On 4 November 2010, Mr Darwazah exercised 100,000 nil cost options, representing 
0.05 per cent. of the issued share capital of the Company, granted to him under 
the Hikma Pharmaceuticals Long Term Incentive Plan 2005 (LTIP). Mr. Darwazah has 
retained all of the shares from the exercise of his LTIP. 
 
The Company was notified of both transactions on 4 November 2010. 
 
Following these transactions Mr. Darwazah holds 473,445 ordinary shares, 
representing 0.25 per cent. of the issued share capital of the Company. 
 
 
                                    - ENDS - 
 
Enquiries: 
 
Hikma Pharmaceuticals PLC 
Henry Knowles                                                 +44 20 7399 2760 
Company Secretary 
 
Susan Ringdal                                                  +44 20 7399 2760 
Investor Relations Director 
 
About Hikma 
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on 
developing, manufacturing and marketing a broad range of both branded and 
non-branded generic and in-licensed products.  Hikma's operations are conducted 
through three businesses: "Branded", "Injectables" and "Generics" based 
principally in the Middle East and North Africa ("MENA") region, where it is a 
market leader, the United States and Europe.  In 2009, Hikma achieved revenues 
of $637 million and profit attributable to shareholders of $78 million.  For 
news and other information, please visit www.hikma.com. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RDSBLBDBSBGBGGS
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.